Two Sigma Investments
ACRV icon

Two Sigma Investments’s Acrivon Therapeutics ACRV Stock Holding History

Two Sigma Investments’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$541K Sell
389,395
-195,674
-33% -$341K ﹤0.01% 3690
2025
Q4 		$1.41M Buy
585,069
+265,864
+83% +$578K ﹤0.01% 2701
2025
Q3 		$578K Buy
319,205
+138,033
+76% +$194K ﹤0.01% 2918
2025
Q2 		$216K Buy
+181,172
New +$249K ﹤0.01% 2892
2023
Q1 		– Sell
-21,534
Closed -$248K – 2923
2022
Q4 		$248K Buy
+21,534
New +$273K ﹤0.01% 2318

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments's ACRV Position: Q1 2026 in Review

Two Sigma Investments reduced its Acrivon Therapeutics (ACRV) stake by 33% in Q1 2026, selling an estimated $341K and leaving 389,395 shares worth $541K. The position accounts for ﹤0.01% of the portfolio, ranked #3690.

Two Sigma Investments first reported a position in ACRV in Q4 2022 and has held it in 5 quarters since. The position peaked at $1.41M in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

  • Two Sigma Investments held 389,395 shares of Acrivon Therapeutics worth $541K as of Q1 2026.
  • Two Sigma Investments sold 195,674 Acrivon Therapeutics shares in Q1 2026, an estimated $341K.
  • Acrivon Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3690 holding.
  • Two Sigma Investments first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Two Sigma Investments's Acrivon Therapeutics position peaked at $1.41M in Q4 2025.
  • 44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.